Dolutegravir is among the better tolerated antiretrovirals, which is a large part of why it became first-line. The effects that do occur cluster around sleep and mood, and they matter more than the trial rates suggested.
What happens in the first weeks?
Headache, nausea and diarrhoea in a minority, generally settling within two to four weeks. Taking the tablet with food helps some people even though it is not required.
What about sleep?
Insomnia, difficulty getting to sleep and vivid or unusual dreams are the most commonly reported effects. They affect a minority and frequently settle over the first month.
Does switching the time help?
For some people considerably. Moving the dose from evening to morning is a simple change worth trying before concluding the drug does not suit you. It works often enough to be the first thing to suggest.
What about mood?
Anxiety, irritability and low mood have been reported, at low rates in trials and substantially higher rates in real-world cohorts. This is a genuine effect rather than a coincidence, and it typically appears within the first weeks.
What should you do about it?
Report it. Do not attribute a mood change after starting treatment to circumstances without mentioning the timing, because switching within or outside the class frequently resolves it. People have endured months of this unnecessarily.
Who is more likely to experience it?
Reporting has been higher in people with existing mental health difficulties, in women and in older people, though the patterns are not fully consistent. If you have a history of depression or anxiety, it is worth flagging before starting.
What about weight gain?
Observed with integrase inhibitors and more pronounced in combination with tenofovir alafenamide. Part reflects a return to health after starting treatment and part appears to be a drug effect, varying considerably between individuals.
Should that stop you taking it?
Not in advance. It is worth monitoring, and if weight changes substantially that is a legitimate reason to discuss alternatives with a different metabolic profile.
What about the kidneys?
Dolutegravir raises blood creatinine slightly by blocking a transporter, without reducing actual kidney function. Clinicians expect a small early rise. A continuing rise warrants investigation, particularly where the regimen also contains tenofovir.
What about lipids?
Generally favourable compared with efavirenz and boosted protease inhibitors. Where lipids rise on a dolutegravir-containing regimen, the other components are frequently responsible.
What about the liver?
Liver enzyme rises occur uncommonly and are monitored, more often in people with hepatitis B or C. Yellowing of the eyes or skin, dark urine or pain under the right ribs warrant prompt contact.
Are there serious reactions?
Hypersensitivity has been reported rarely. Any rash with fever, blistering, peeling skin, or involvement of the mouth or eyes is an emergency needing immediate attention rather than a call in the morning.
What monitoring is there?
Blood tests every three to six months covering viral load, kidney and liver function and lipids, with weight recorded. Most changes appear on a test before anyone notices a symptom.
Should you look side effects up online?
The patient information leaflet lists everything ever reported, which makes it alarming and unhelpful for judging likelihood. A clinic pharmacist will tell you which effects are common and which matter, in about two minutes.
What is worth recording?
When something started, how long it lasts, and whether anything else changed at the same time. A short note is considerably more useful at an appointment than trying to reconstruct whether a symptom followed starting dolutegravir or something else.
Are side effects a reason to stop?
Not to stop, and often a reason to change. Stopping leaves you untreated; switching keeps you covered. Nearly every effect described here has an alternative regimen that avoids it, so the conversation is worth having.
Do experiences differ between people?
Substantially. Two people on identical regimens can have completely different experiences, which is why general descriptions only go so far. Your own first month is more informative than any list of possibilities.